BACKGROUND: Despite the availability of potent antiretroviral regimens (combination antiretroviral therapy [cART]), HIV-associated neurocognitive disorders (HAND) are increasingly recognized. Our aim was to investigate the prevalence and treatment-related correlates of HAND, exploring the potential neurotoxicity of antiretrovirals on cognitive functions. METHODS: We performed a cross-sectional single cohort study by consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits. Each patient was submitted to a comprehensive neuropsychological battery and was considered cognitively impaired on the basis of results obtained in matched healthy HIV-negative subjects. CNS penetration effectiveness (CPE) rank was calculated for cART regimens according to 2010 CHARTER criteria. Factors associated with cognitive impairment were investigated by linear or logistic regression analysis. RESULTS: A total of 146 patients were enrolled. Of these, 129 (88.4%) were on cART and 59.6% of them were on current regimen from ≥1 year. Sixty-nine patients (47%) were classified as cognitively impaired (35.6% asymptomatic and 11.6% mild neurocognitive impairment). In the multivariate analysis, efavirenz use (odds ratio [OR] = 4.00; p = 0.008) and non-Italian nationality (OR = 3.46; p = 0.035) were associated with increased risk of cognitive impairment, whereas higher education was associated with a lower risk (OR = 0.85; p = 0.002). Furthermore, efavirenz use and age ≥65 years independently predicted worse performance on the double barrage and the Stroop test (time). No association between CPE rank and cognitive impairment was observed. CONCLUSIONS: A high prevalence of HAND was observed in apparently asymptomatic HIV+ individuals. HAND was associated with efavirenz use, suggesting the potential neurotoxicity of this drug. Routine neuropsychological examinations could help clinicians make correct diagnoses and manage mild, but clinically relevant, forms of HAND.
BACKGROUND: Despite the availability of potent antiretroviral regimens (combination antiretroviral therapy [cART]), HIV-associated neurocognitive disorders (HAND) are increasingly recognized. Our aim was to investigate the prevalence and treatment-related correlates of HAND, exploring the potential neurotoxicity of antiretrovirals on cognitive functions. METHODS: We performed a cross-sectional single cohort study by consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits. Each patient was submitted to a comprehensive neuropsychological battery and was considered cognitively impaired on the basis of results obtained in matched healthy HIV-negative subjects. CNS penetration effectiveness (CPE) rank was calculated for cART regimens according to 2010 CHARTER criteria. Factors associated with cognitive impairment were investigated by linear or logistic regression analysis. RESULTS: A total of 146 patients were enrolled. Of these, 129 (88.4%) were on cART and 59.6% of them were on current regimen from ≥1 year. Sixty-nine patients (47%) were classified as cognitively impaired (35.6% asymptomatic and 11.6% mild neurocognitive impairment). In the multivariate analysis, efavirenz use (odds ratio [OR] = 4.00; p = 0.008) and non-Italian nationality (OR = 3.46; p = 0.035) were associated with increased risk of cognitive impairment, whereas higher education was associated with a lower risk (OR = 0.85; p = 0.002). Furthermore, efavirenz use and age ≥65 years independently predicted worse performance on the double barrage and the Stroop test (time). No association between CPE rank and cognitive impairment was observed. CONCLUSIONS: A high prevalence of HAND was observed in apparently asymptomatic HIV+ individuals. HAND was associated with efavirenz use, suggesting the potential neurotoxicity of this drug. Routine neuropsychological examinations could help clinicians make correct diagnoses and manage mild, but clinically relevant, forms of HAND.
Authors: Assawin Gongvatana; Ronald A Cohen; Stephen Correia; Kathryn N Devlin; Jadrian Miles; Hakmook Kang; Hernando Ombao; Bradford Navia; David H Laidlaw; Karen T Tashima Journal: J Neurovirol Date: 2011-10-01 Impact factor: 2.643
Authors: Howard A Crystal; Jeremy Weedon; Susan Holman; Jennifer Manly; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Wendy J Mack; Elizabeth Golub; Jason Lazar; Ann Ho; Mary Jeanne Kreek; Robert C Kaplan Journal: J Neurovirol Date: 2011-10-18 Impact factor: 2.643
Authors: Yijia Li; Zheng Wang; Yu Cheng; James T Becker; Eileen Martin; Andrew Levine; Leah H Rubin; Ned Sacktor; Ann Ragin; Ken Ho Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Savvas Andronikou; Christelle Ackermann; Barbara Laughton; Mark Cotton; Nicollette Tomazos; Bruce Spottiswoode; Katya Mauff; John M Pettifor Journal: Childs Nerv Syst Date: 2014-05-23 Impact factor: 1.475
Authors: Knut A Hestad; Jonathan Chinyama; Menon J Anitha; Mary S Ngoma; J Allen McCutchan; Donald R Franklin; Robert K Heaton Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi Journal: HIV Med Date: 2014-02-24 Impact factor: 3.180
Authors: Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll Journal: HIV Clin Trials Date: 2018-11-19
Authors: Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke Journal: J Neurovirol Date: 2015-11-16 Impact factor: 2.643